{
    "organizations": [],
    "uuid": "aa690afd0f5f869f9810b9baa7f2f7ebe8cabff2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-argos-therapeutics-reports-results/brief-argos-therapeutics-reports-results-of-interim-analysis-of-the-adapt-trial-and-announces-review-of-strategic-alternatives-idUSASC09WGZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic Alternatives",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Argos Therapeutics Inc:\n* ARGOS THERAPEUTICS REPORTS RESULTS OF INTERIM ANALYSIS OF THE ADAPT TRIAL AND ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES\n* ARGOS THERAPEUTICS INC - COMPANY TO TERMINATE ADAPT STUDY\n* ARGOS THERAPEUTICS INC - COMPANY HAS RETAINED STIFEL TO PROVIDE ADVICE ON POSSIBLE STRATEGIC ALTERNATIVES\n* ARGOS THERAPEUTICS INC - TRADING IN COMMON STOCK TO BE TRANSFERRED FROM NASDAQ TO OTCQB VENTURE MARKET\n* ARGOS THERAPEUTICS - STRATEGIC ALTERNATIVES MAY INCLUDE A POTENTIAL MERGER OR SALE OF CO\n* ARGOS - ESTIMATED MEDIAN OVERALL SURVIVAL FOR COMBO ARM WAS 28.2 MONTHS VERSUS 31.2 MONTHS FOR CONTROL ARM IN MOST RECENT ANALYSIS OF ADAPT TRIAL DATA\n* ARGOS - TWO OTHER CO-PRIMARY ENDPOINTS IN ADAPT TRIAL ALSO DID NOT DEMONSTRATE A FAVORABLE RESULT\n* ARGOS - FOURTH ENDPOINT, FIVE-YEAR SURVIVAL, WAS NOT EVALUATED IN ADAPT TRIAL AS THERE WAS INSUFFICIENT DATA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T20:07:00.000+03:00",
    "crawled": "2018-04-20T12:03:26.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "argo",
        "therapeutic",
        "inc",
        "argo",
        "therapeutic",
        "report",
        "result",
        "interim",
        "analysis",
        "adapt",
        "trial",
        "announces",
        "review",
        "strategic",
        "alternative",
        "argo",
        "therapeutic",
        "inc",
        "company",
        "terminate",
        "adapt",
        "study",
        "argo",
        "therapeutic",
        "inc",
        "company",
        "retained",
        "stifel",
        "provide",
        "advice",
        "possible",
        "strategic",
        "alternative",
        "argo",
        "therapeutic",
        "inc",
        "trading",
        "common",
        "stock",
        "transferred",
        "nasdaq",
        "otcqb",
        "venture",
        "market",
        "argo",
        "therapeutic",
        "strategic",
        "alternative",
        "may",
        "include",
        "potential",
        "merger",
        "sale",
        "co",
        "argo",
        "estimated",
        "median",
        "overall",
        "survival",
        "combo",
        "arm",
        "month",
        "versus",
        "month",
        "control",
        "arm",
        "recent",
        "analysis",
        "adapt",
        "trial",
        "data",
        "argo",
        "two",
        "endpoint",
        "adapt",
        "trial",
        "also",
        "demonstrate",
        "favorable",
        "result",
        "argo",
        "fourth",
        "endpoint",
        "survival",
        "evaluated",
        "adapt",
        "trial",
        "insufficient",
        "data",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}